Vanberra Signal

Gentrepid

Curated by Signal

Tool for candidate 'disease gene' prediction

Overview

Gentrepid is a tool for candidate 'disease gene' prediction aimed at researchers looking to narrow down their list of candidate disease genes that are located in their region of interest on the genome that has been found to be associated with a particular phenotype or disease. It uses Common Module Profiling (CMP) and Common Pathway Scanning (CPS) algorithms. CMP uses a domain-based approach to identify genes with a potential functional similarity to known disease genes and is based on the hypothesis that genes of similar function will lead to the same phenotype while CPS is based on the assumption that common phenotypes are associated with proteins that participate in the same complex or pathway.

Key facts

Founded
2006

Business model

More on Vanberra Signal

Members only

Competitors & similar companies

More Life Sciences Technology companies
  • Medical image analysis software for cancer risk assessment, prognosis & diagnosis

    Life Sciences TechnologyCambridge, United Kingdom
  • Provider of point-of-care test for cancer diagnosis

    Life Sciences TechnologyLondon, United Kingdom
  • Blood glucose monitoring system

    Life Sciences TechnologyPeterborough, United Kingdom

About Gentrepid

What does Gentrepid do?

Gentrepid is a tool for candidate 'disease gene' prediction aimed at researchers looking to narrow down their list of candidate disease genes that are located in their region of interest on the genome that has been found to be associated with a particular phenotype or disease.

Where is Gentrepid headquartered?

Gentrepid is headquartered in Worcester Park, United Kingdom.

When was Gentrepid founded?

Gentrepid was founded in 2006.

Which sector is Gentrepid in?

Gentrepid operates in Life Sciences Technology.

Who are Gentrepid's competitors?

Companies similar to Gentrepid include TexRAD, Cansor, and Palmdoc.